Centessa Pharmaceuticals plc - ADR CNTA

NAS: CNTA | ISIN: US1523091007   13/08/2025
17,14 USD (+0,18%)
(+0,18%)   13/08/2025

12 augustus 2025 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 · Persbericht

16 juni 2025 · Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year · Persbericht

14 mei 2025 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 · Persbericht

24 maart 2025 · Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 · Persbericht

12 november 2024 · Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update · Persbericht

13 september 2024 · Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares · Persbericht

11 september 2024 · Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares · Persbericht

10 september 2024 · Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers · Persbericht

27 augustus 2024 · Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) · Persbericht

13 augustus 2024 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 · Persbericht

13 mei 2024 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 · Persbericht

24 april 2024 · Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares · Persbericht

23 april 2024 · Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares · Persbericht

22 april 2024 · Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 · Persbericht

28 maart 2024 · Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 · Persbericht

10 december 2023 · Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia · Persbericht

13 november 2023 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 · Persbericht

25 oktober 2023 · Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders · Persbericht

14 augustus 2023 · Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 · Persbericht

10 juli 2023 · Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors · Persbericht

Mijn selecties